stop_circleTerminated/Withdrawn

Acute respiratory distress syndrome

Study to find the highest safe dose of soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 administered as multiple doses by inhalation to patients who cannot breathe by their own and suffer from a type of lung failure that causes fluid to build up in the lungs making breathing difficult (ARDS)

Trial purpose

With this study researchers want to find the highest safe dose of the soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 and how safe and well the study drug works. Furthermore researchers want to gather information on the way the body absorbs, distributes and gets rid of the study drug given as increasing multiple doses by inhalation to patients who cannot breathe by their own and suffer from a type of lung failure that causes fluid to build up in the lungs making breathing difficult (ARDS)

Key Participants Requirements

Sex

All

Age

18 - N/A

Trial summary

Enrollment Goal
16
Trial Dates
November 2020 - September 2023
Phase
Phase 1
Could I Receive a placebo
No
Products
BAY1211163
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Klinikum der Stadt Köln gGmbH - Krankenhaus MerheimKöln, 51109, Germany
Completed
Charité - Universitätsmedizin BerlinBerlin, 10117, Germany
Completed
Universitätsklinikum Giessen und MarburgGießen, 35392, Germany
Completed
Sana-Klinikum Remscheid|Kardio, Angio, Pneumo u. IntensivmedRemscheid, 42859, Germany
Withdrawn
Universitätsklinikum EssenEssen, 45147, Germany
Withdrawn
Universitätsklinikum Schleswig-Holstein (UKSH)Kiel, 24105, Germany

Primary Outcome

  • Numbers of participants with treatment emergent adverse events (TEAEs)
    date_rangeTime Frame:
    Up to 9 days
  • Numbers of participants with dose limiting events (DLEs)
    A dose limiting event is defined as any of the TEAEs occurring during dosing with BAY1211163 and regarded by the investigators to be related to BAY1211163.
    date_rangeTime Frame:
    Day 1 to 7 (may include Day 8)

Secondary Outcome

  • Values of oxygenation index (OI)
    The Oxygenation Index (OI) is calculated by using the fraction of inspired oxygen (FiO2), the partial pressure of oxygen in arterial blood (PaO2) and the mean airway pressure (MPAW)
    date_rangeTime Frame:
    Up to 28 days

Trial design

Safety and tolerability of adaptive escalating multiple doses (three times daily) of a soluble Guanylate Cyclase (sGC) Activator Inhale, BAY 1211163, as inhalation in intubated and mechanically ventilated adult patients with moderate and severe Acute Respiratory Distress Syndrome (ARDS). A pilot (phase Ib), first in patient, open label study
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
Single Group Assignment
Trial Arms
1